Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.

Abstract

We carried out a clinical trial of 1 alpha-hydroxycholecalciferol [1 alpha(OH)D3] at a dose of 1.0 microgram a day on 7 patients with psoriasis vulgaris. These patients had been treated by topical applications of corticosteroids before this study without improvement, and during the clinical trial, treatment of topical corticosteroids was continued on 6 of the 7 patients. Four of 7 patients showed complete remission and marked improvement and 2 additional patients showed minimal improvement of their skin lesions during and after the treatment with 1 alpha(OH)D3. No adverse reactions were noted during the treatment period. The mechanism of the phenomenon we observed has yet to be elucidated. Controlled trials of large numbers of patients with psoriasis vulgaris treated with 1 alpha(OH)D3 are under way.

• Authors: S Takamoto, T Onishi, S Morimoto, S Imanaka, S Yukawa, T Kozuka, Y Kitano, Y Seino, Y Kumahara
• Journal: Calcified tissue international (Calcif Tissue Int) Vol. 39 Issue 6 Pg. 360-4 (Dec 1986) ISSN: 0171-967X [Print] United States
• PMID: 3100000 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Hydroxycholecalciferols
• alfacalcidol

Topics

• Administration, Oral
• Administration, Topical
• Adrenal Cortex Hormones (administration & dosage, therapeutic use)
• Adult
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Hydroxycholecalciferols (administration & dosage, adverse effects, therapeutic use)
• Male
• Middle Aged
• Psoriasis (blood, drug therapy)